Literature DB >> 20532534

TCF-3, 4 protein expression correlates with beta-catenin expression in MSS and MSI-H colorectal cancer from HNPCC patients but not in sporadic colorectal cancers.

Peter Balaz1, Jens Plaschke, Stefan Krüger, Heike Görgens, Hans K Schackert.   

Abstract

PURPOSE: The beta-catenin-T-cell factor-4 (TCF-4) complex is the main control switch of cell proliferation and differentiation of normal and malignant intestinal cells. The aim of our study was to analyze the protein expression of components of the Wnt pathway in microsatellite stable (MSS) and highly unstable (MSI-H) sporadic and hereditary nonpolyposis colorectal cancer (HNPCC) in human colorectal cancers.
METHODS: Sixty seven colorectal tumors comprising of 15 sporadic MSS, 12 sporadic microsatellite instability colorectal tumors and 40 tumors from HNPCC patients, of which 20 were MSS and 20 MSI-H, were analyzed for the expression of APC, beta-catenin, and TCF-3, 4 proteins by immunohistochemistry.
RESULTS: We found a significant difference in cytoplasmic APC expression frequency between sporadic MSS (52%) and HNPCC tumors (78%), whereas no difference was detected between MSI-H and MSS or HNPCC tumors. All tumor groups showed a similar pattern of decreased membranous staining and increased cytoplasmic and nuclear staining for beta-catenin compared to normal cells. Moreover, the TCF-3, 4 protein expression was higher (43%) in HNPCC-associated MSS tumors compared to sporadic tumors (14%; analysis of variance (ANOVA) p < 0.05). For HNPCC tumors, the subcellular beta-catenin expression (membranous, cytoplasmic, and nuclear) correlated with the nuclear TCF-3, 4 signal in MSS tumors (Spearman correlation p < 0.0007) and MSI-H tumors (Spearman correlation p < 0.0001).
CONCLUSION: We have shown a previously unknown difference in TCF-3, 4 protein expression between sporadic and HNPCC MSS tumors. In addition, we found no difference in nuclear beta-catenin signal intensity, which may be caused by an alteration in Wnt pathway in MSS sporadic tumors by unknown mechanisms leading to lower TCF-3, 4 protein expression. This hypothesis has to be tested in future investigations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20532534     DOI: 10.1007/s00384-010-0959-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  32 in total

Review 1.  Linking colorectal cancer to Wnt signaling.

Authors:  M Bienz; H Clevers
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Altered distribution of beta-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers.

Authors:  D E Aust; J P Terdiman; R F Willenbucher; K Chew; L Ferrell; C Florendo; A Molinaro-Clark; G B Baretton; U Löhrs; F M Waldman
Journal:  Mod Pathol       Date:  2001-01       Impact factor: 7.842

3.  Apoptosis and APC in colorectal tumorigenesis.

Authors:  P J Morin; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

4.  Redefining the subcellular location and transport of APC: new insights using a panel of antibodies.

Authors:  Mariana Brocardo; Inke S Näthke; Beric R Henderson
Journal:  EMBO Rep       Date:  2005-02       Impact factor: 8.807

5.  Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription.

Authors:  Rina Rosin-Arbesfeld; Adam Cliffe; Thomas Brabletz; Mariann Bienz
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

6.  Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin.

Authors:  Hai-Ri Li; Elena I Shagisultanova; Kentaro Yamashita; Zhe Piao; Manuel Perucho; Sergei R Malkhosyan
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

7.  Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate beta-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling.

Authors:  Masashi Idogawa; Mitsuko Masutani; Miki Shitashige; Kazufumi Honda; Takashi Tokino; Yasuhisa Shinomura; Kohzoh Imai; Setsuo Hirohashi; Tesshi Yamada
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway.

Authors:  Jia-Hao Xiao; Corine Ghosn; Cory Hinchman; Chad Forbes; Jenny Wang; Nonna Snider; Allison Cordrey; Yi Zhao; Roshantha A S Chandraratna
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

9.  Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.

Authors:  Gillian Smith; Francis A Carey; Julie Beattie; Murray J V Wilkie; Tracy J Lightfoot; Jonathan Coxhead; R Colin Garner; Robert J C Steele; C Roland Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

10.  The adenomatous polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration.

Authors:  I S Näthke; C L Adams; P Polakis; J H Sellin; W J Nelson
Journal:  J Cell Biol       Date:  1996-07       Impact factor: 10.539

View more
  2 in total

1.  Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation.

Authors:  Christina Therkildsen; Anna Isinger-Ekstrand; Steen Ladelund; Anja Nissen; Eva Rambech; Inge Bernstein; Mef Nilbert
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

2.  Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X.

Authors:  Stefan Haraldsson; Louise Klarskov; Mef Nilbert; Inge Bernstein; Jesper Bonde; Susanne Holck
Journal:  BMC Clin Pathol       Date:  2017-08-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.